Intervention from Paris secures French future for Aventis
May 7, 2004Aventis has dropped its long-running opposition to a takeover bid by French compatriots Sanofi-Synthlabo after the offer to its shareholders …
OTC Zocor to be cleared but divisions persist
April 28, 2004The government is shortly to announce the approval of the world's first over-the-counter statin, Zocor Heart Pro, but is unlikely …
Burson-Marsteller to launch cancer treatment in the UK
April 28, 2004Burson-Marsteller, a subsidiary of the WPP advertising giant, has been appointed PR campaign handler for the UK launch of Velcade, …
Patients still being denied access to colon cancer treatments
April 28, 2004A new Roche-sponsored survey of patients with bowel cancer has found that most are still not being consulted on the …
BMA chairman warns reforms add to threat of ‘two-tier NHS’
April 26, 2004The chairman of the BMA has warned that new reforms are adding to the threat of a two-tier NHS posed …
US legal action Aventis’ latest weapon in repelling Sanofi
April 26, 2004Aventis has unleashed its latest stratagem in resisting Sanofi-Synthleabo's hostile takeover bid, a US legal action claiming its rival has …
A tale of two pills for Pfizer in Q1
April 26, 2004Pfizer, torceptrapib
The first quarter of 2004 saw Pfizer’s biggest seller Lipitor extend its domination of the statin market but Viagra, another …
Aventis’ Apidra approved in US
April 26, 2004The FDA has approved Aventis' rapid-acting insulin analogue Apidra, ahead of an anticipated August approval by the EMEA, as the …
No change one year on from NSF, says diabetes charity
April 26, 2004One year on from the launch of the National Service Framework (NSF) for Diabetes, the planning of care has improved …
Wyeth’s Zoton hot on the heels of over-the-counter Zanprol
April 26, 2004Wyeth, manufacturers of the UK's biggest selling prescription drug Zoton plan to take the drug POM-P, hot on the heels …
The brave new GMS world
April 26, 2004The new General Medical Services contract (nGMS) started officially on 1st April, though its far-reaching effects may be far from …
Supporting the everyday experts
April 26, 2004We are all familiar with the growth of the ageing population during the second half of the 20th century and …
Sanofi slims down portfolio in preparation for Aventis acquisition
April 15, 2004Sanofi-Synthelabo has agreed to sell two of its products to GlaxoSmithKline, as it seeks to avoid potential problems with competition …
Britannia and Otsuka collaborate on autoimmune disease treatment
April 15, 2004Britannia Pharmaceuticals has entered into an agreement with Otsuka Pharmaceuticals UK to manage the UK distribution of the novel treatment …
Heart concerns halt Acambis trials
April 15, 2004UK biotech Acambis has suspended Phase III clinical trials of its smallpox vaccine after three patients suffered a heart inflammation …
Avastin gets off to a flying start
April 15, 2004US biotech Genentech's first quarter results have surpassed estimates as the company posted profit growth of 17% to $176.6 million, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
